A c c e p t e d M a n u s c r i p t Subcutaneous anaplasmosis vaccine for cattle 3 ABSTRACT: Bovine anaplasmosis is the most prevalent tick-transmitted disease of cattle worldwide and a major obstacle to profitable beef production. Use of chlortetracyclinemedicated feed to control active anaplasmosis infections during the vector season has raised concerns about the potential emergence of antimicrobial resistance in bacteria that may pose a risk to human health. Furthermore, the absence of effectiveness data for a commercially available, conditionally licensed anaplasmosis vaccine is a major impediment to implementing anaplasmosis control programs. The primary objective of this study was to develop a single-dose vaccine delivery platform to produce long-lasting protective immunity against anaplasmosis infections. Twelve Holstein steers, aged 11-12 weeks, were administered a novel 3-stage, single-dose vaccine against Anaplasma marginale (Am) major surface protein 1a. The vaccine consisted of a soluble vaccine administered subcutaneously (s.c.) for immune priming, a vaccine depot of a biodegradable polyanhydride rod with intermediate slow release of the vaccine for boosting immune response, and an immuneisolated vaccine platform for extended antigen release (VPEAR implant) deposited s.c. in the ear. Six calves were randomly assigned to two vaccine constructs (n=3) that featured rods and implants containing a combination of two different adjuvants, diethylaminoethyl (DEAE)-Dextran and Quil-A (Group A). The remaining 6 calves were randomly assigned to two vaccine constructs (n=3) that featured rods and implants containing the same adjuvant (Uilenberg, 1995; Kocan et al. 2003) . In the absence of an effective vaccine, control of anaplasmosis infection is predicated on the administration of low doses of in-feed chlortetracycline for several months (Reinbold et al. 2010b ). As of January 2017, control of active anaplasmosis using in-feed chlortetracycline requires veterinary oversight in the form of a veterinary feed directive (VFD). As a result, federal law restricts this medicated feed to use by or on the order of a licensed veterinarian (FDA, 2019) . The VFD places an additional regulatory burden on livestock producers and makes anaplasmosis control in extensive and smaller livestock operations especially challenging.
Vaccination strategies to control anaplasmosis are urgently needed to assist livestock producers in combating this disease. Major surface protein (MSP) 1a (MSP1a) is one of six MSP previously described on Am derived from bovine erythrocytes and is involved in immunity to Am infection in cattle (Palmer et al. 1987) . Previous work has shown that cattle vaccinated with erythrocyte-derived Am antigens demonstrated preferential recognition for MSP1a (Brown et al. 2001 ). The present study was conducted to determine the optimal delivery and adjuvant combination of Am MSP1a using a 3-stage vaccine administered as a single injection and long-term subcutaneous (s.c.) ear implant. The unique vaccine implant design allows for a sustained release of the target antigen with an immunoregulatory design to minimize tolerance and achieve long-term Downloaded from https://academic.oup.com/jas/advance-article-abstract/doi/10.1093/jas/skz392/5691273 by 04860000 user on 06 January 2020 A c c e p t e d M a n u s c r i p t Subcutaneous anaplasmosis vaccine for cattle 5 immunization in a single dose. We hypothesize that this device will mimic the life-long concomitant immunity associated with persistent Am infection after field exposure.
MATERIALS AND METHODS
All animal studies were conducted under an approved Institutional Animal Care and Use Committee (IACUC) protocol (IACUC #: 3959) on file at Kansas State University, Manhattan, Kansas.
Antigen
The peptide antigen R1OK was designed from an Am strain originally isolated from a cow in Oklahoma as previously described by Blouin et al. (2000) and characterized by de la Fuente et al. 
Rod and implant design
The boosting dose relied on a bioerodible polyanhydride (PA) rod 15mm long and 4mm in diameter composed of 20% 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 80% 1,6-bis(p- mixtures of all components were pressed in a custom-made mold at 0.5 tons-on-ram for 5 s, using a hydraulic press (International Crystal Laboratories Inc., Garfield, NJ). The implant was designed and formulated as previously described (Schaut et al. 2018 ). All but three calves required implant replacement after initial rejection. Rejections were preceded by local inflammation and formation of an abscess around the implant sites. Implant replacements were of identical design to the original implant, except the amount of adjuvant was reduced to either 10 mg of DEAE-Dextran or 50 µg of Quil-A.
Study Animals
A cohort of 12 Holstein steers ranging from 11-12 weeks of age, weighing 102.1 ± 2.3 kg (mean ± SEM) was enrolled in the project. Calves were randomly assigned to vaccine treatment groups using the RAND function in a spreadsheet program (Microsoft Excel, Richmond, WA). Six calves were assigned to two vaccine constructs that featured rods and implants containing a combination of different adjuvants (DEAE-Dextran and Quil-A) (Group A). The remaining 6 calves were randomly assigned to two vaccine constructs that featured rods and implants containing the same adjuvant (either DEAE-Dextran or Quil A) (Group B). All calves received an initial soluble vaccine priming dose s.c. before implantation (See Table 1 ). As this was a proof-of-concept study conducted over 2 years and animal numbers were limited, we did not enroll a negative control group to evaluate the differences in composition of the vaccine constructs.
Animal vaccinations
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The soluble vaccine was administered into the s.c. tissue on the right side of the neck.
Immediately afterward, the rod was inserted into the s.c. tissue at the base of the right ear pinna through a six-gauge needle; the implant was then manually inserted through the same incision. The incision was closed with a single suture. Reimplantation, when required, was done into the left (contralateral) ear, five weeks after the initial implant. All but three calves required reimplantation within the first 5 weeks of the study with devices containing a reduced adjuvant load. All implants were subsequently maintained for the duration of the study, suggesting that rejection may have been due to excessive activation of an immune response to the initial implant device.
Reimplantation was not believed to impact total antigen delivery as the rate of release from the implants was engineered to remain consistent for the duration of the study regardless of whether the device was reimplanted.
Anaplasma marginale infection challenge
A cryopreserved field isolate of Am, with the MSP1a genotype M-F-F, was administered IV at 21 months after vaccination to infection challenge immunized animals. This represented day zero of the infection challenge phase of the study. Calves weighed a mean ± SEM of 632.7 kg ± 16.3 kg and were approximately 24 months of age at the time of challenge. The Am challenge isolate was obtained from a persistently-infected cow in Oklahoma in 2017. Briefly, to prepare the cryopreserved Am isolate, 60 mL of blood from the donor cow was collected into a blood bag containing heparin and sub-inoculated into a splenectomized calf to amplify Am. The resulting infected red blood cells were washed three times in phosphate buffered saline (PBS), resuspended 1:1 in a stabilate buffer (31.2% dimethylsulfoxide in 1X PBS) after the final wash, and stored in liquid nitrogen as described by Love (1972) . Two milliliters of cryopreserved Am (M-F-F genotype) stabilate were intravenously inoculated into the jugular vein of each vaccinated steer. The target
Am challenge dose was approximately 2 x 10 9 bacteria per inoculation. Am gene MSP5 was used to quantify Am infection levels in blood as previously described (Hammac et al. 2013) . Quantitative specificity for this qPCR assay is 100 copies per template and qualitative sensitivity is 10 copies per template. Serum was centrifuged at 2,000 x g for 10 min at 20°C from whole blood collected into evacuated tubes containing no anticoagulant. Serum samples were submitted to the Iowa State University Veterinary Diagnostic Laboratory (Ames, IA) for Am serological screening using a commercial cELISA that detects host antibodies produced against Am MSP5 (Catalog No: 283-2, VMRD, Pullman, WA).
Sampling

Animal Health
Anaplasmosis is potentially fatal, and animal health was monitored closely to determine need for antibiotic intervention. Animal PCV and rectal temperature were measured twice per week.
Veterinary exams were performed if: temperatures measured greater than 39.2 o C or less than 36.7 o C, PCV was measured at less than 22%, respiration rate was measured at greater than 60 breaths per minute, inappetence was noted for more than 24 hours, or if severe depression was observed for more than 24 hours. Veterinary physical exams included verification of symptoms in A Fisher's exact test was also used for comparison between vaccine constructs.
RESULTS AND DISCUSSION
The effect of vaccine treatment group alone was examined but no differences were found when comparing bacteremia (P = 0.136) or body temperature (P = 0.068). Animals administered the combination adjuvant vaccine construct had higher PCV than those receiving the single adjuvant vaccine construct at day 35 post-infection (P = 0.006) (Figure 1) . Bacteremia peak coincided with A c c e p t e d M a n u s c r i p t Subcutaneous anaplasmosis vaccine for cattle 10 PCV nadir (Figure 1) . It is noteworthy that a chi-squared test without Yate's correction revealed that animals vaccinated with combination adjuvants (vaccine construct A) were less likely to require antibiotic intervention compared with calves vaccinated with single adjuvants (vaccine construct B) (P = 0.014). A Fisher's exact test revealed a similar trend (P = 0.061), as did a chi-squared test with Yate's correction (P = 0.066). These results indicate that calves exhibited diminished clinical signs of anaplasmosis when vaccine antigen was delivered with a combination of adjuvants as opposed to a single adjuvant.
These results are in agreement with previous studies that indicated that immunization with native MSP1 (a heterodimer containing disulfide and noncovalently bonded polypeptides MSP1a and MSP1b) of the erythrocytic stage of Am conferred protection against pathogen challenge (Palmer et al. 1986 ). Likewise, Hope et al. (2004) demonstrated the value of using multiple adjuvants to confer immunity and decrease the need for antibiotic intervention in infected animals. This may be due to a broader repertoire of immune effector cells being stimulated by multiple adjuvants. Previous work has suggested that Quil-A (a heterogenous fraction of saponin) induces activation of dendritic cells and leads to strong antibody and T cell responses (Maraskovsky et al., 2009) . Though mode of action hasn't been studied in detail, DEAE-Dextran has shown antibody enhancing properties in anti-fertility vaccines (Vizcarra et al., 2012) and appears to stimulate antigen-specific antibodies and eosinophilia when used in helminth vaccines (Piedrafita et al., 2013) .
Assuming vaccine efficacy is based on a reduced need for antimicrobial therapy and increased survival, our data indicate that the use of multiple adjuvants in the vaccine construct could limit disease severity. Though caution is necessary considering the small sample size, it is noteworthy that 100% (6/6) of the animals vaccinated using a single adjuvant (DEAE-Dextran or QuilA) required antibiotic intervention during the study, compared to only 33% (2/6) of animals vaccinated using combination adjuvants (DEAE-Dextran and QuilA). Despite the documented negative impact of anaplasmosis in cattle herds (Alderink et al. 1982) , there remains no effective means of disease prevention. Controlling the disease once endemic is challenging, as transmission of Am can be mediated through biological vectors such as ticks (Dikmans, 1950) , mechanical vectors such as horseflies (Baldacchino et al. 2014 ), bloodcontaminated fomites such as needles (Reinbold et al. 2010a ), or transplacentally from cow to calf during gestation (Zaugg, 1985) . Average weight loss associated with disease progression is reported to be 190 lbs. (Alderink et al. 1982) with adult (>2yrs of age) cattle being more susceptible to severe clinical disease and death (Kocan et al. 2003) . Symptoms diminish in surviving animals, but recovered cattle maintain low, sometimes undetectable, levels of infection (Coetzee et al. 2005) .
These carrier animals subsequently serve as local reservoirs for disease transmission (Swift and Thomas, 1983) . Previous work has estimated that, when introduced to a naïve herd, anaplasmosis can result in a 3.6% reduction in calf crop, a 30% increase in cull rate, and a 3% mortality rate in clinically infected adult cattle (Alderink et al. 1982) . In spite of these challenges, strategies to control anaplasmosis have not changed markedly in the last several decades (Kocan et al. 2003) .
Though not available in the U.S., use of live vaccines containing attenuated or less pathogenic strains of Am or A. centrale for the control of clinical anaplasmosis is widespread in many parts of the world (Rogers et al. 1988 ). These vaccines are predicated on the principle of concomitant immunity, the paradoxical immune status in which resistance to reinfection coincides with the persistence of the original infection. Live vaccine-vaccinated cattle develop persistent infections which induce lifelong protective immunity in cattle such that revaccination is usually not required (Shkap et al. 2008) . Although generally effective, use of live Am vaccines is not legal in the U.S.
There are currently no USDA-approved vaccines for protection against Am infection or lowering disease severity. An experimental killed vaccine is available in 14 U.S. states, but no efficacy data for this vaccine are available (Aubry and Geale, 2011) . Killed vaccines that contain purified Am organisms from erythrocytes are expensive to manufacture, may have the potential to induce isoimmune erthrolysis following repeated administration, have unknown efficacy against A c c e p t e d M a n u s c r i p t heterologous strains, and usually require annual revaccination (Kocan et al. 2003) . Thus, there remains no vaccine universally accepted as safe and effective against bovine anaplasmosis (Hammac et al. 2013 ).
This study tested the efficacy of a set of s.c. vaccine implants to protect against the development of antibiotic-intervention-requiring clinical anaplasmosis. Work presented here agrees with previous studies using cell culture-derived Am antigens (Kocan et al. 2001) . Six MSPs of Am have been identified on erythrocyte-derived organisms (Kocan et al. 2003 (Santos et al. 2013) . It is possible that we would have observed a more robust protective response if we had used an Am strain that contained the K;S tandem repeat sequence, as the B and T cell epitopes differ between K;S, M and F tandem repeats (Catanese et al. 2016 ).
In the present study, our group demonstrated the feasibility of a subunit-based vaccine delivered in a single, subcutaneous ear implant 21 months prior to disease challenge. Future work may expand upon this observation by incorporating other conserved antigens, such as those previously identified (Riding et al. 2003 ) utilizing a similar vaccine delivery platform. Future work may also establish an optimal adjuvant concentration in order to achieve high immunogenicity without implant rejection. 
